CCR2 and prostate carcinoma: Carlumab (CNTO 888), a human monoclonal anti-CCL2 antibody, was well-tolerated but did not block the CCL2/CCR2 axis or show antitumor activity as a single agent in metastatic castration-resistant prostate cancer [43].